Investigating the Physiological Effects of Weight Loss on Male Fertility
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
North West London, United Kingdom, W12 0HS
- Imperial College NHS Healthcare Trust
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Body mass index (BMI) ≥ 30 kg/m^2 [Part: 1, 2& 3]
- Evidence of reduced reproductive capacity (e.g. reduced sperm concentration [applicable for study B]
Exclusion Criteria:
- History of undescended testes, testicular surgery or mumps infection
- Hormonal therapy such as testosterone or selective oestrogen receptor modulators
- History of systemic cytotoxic therapy or pelvic radiotherapy
- Chronic systemic disease, such as cardiac, renal or liver failure
- At least one of the following:
Alcohol intake >30 units per week Smoking daily Recreational drug use at a frequency not less than weekly
- Acute illness likely to affect the result of study
- Impaired ability to provide full consent to take part in the study
- An occupation requiring strenuous physical exercise that may require a high energy diet
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Low Energy Diet
Commercially available diet products
|
Caloric restriction to achieve weight loss
|
|
Other: NHS advice on healthy eating
Dietary / lifestyle advice programme
|
Advice on energy requirements as per the British Dietetic Association
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sperm Concentration
Time Frame: 16 weeks
|
The number of sperm per millimeter of semen.
Sperm concentration is an important factor affecting male fertility.
It is calculated on a standard semen analysis
|
16 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total Motility
Time Frame: 16 weeks
|
Total motility refers to the percentage of sperm making any sort of movement.
|
16 weeks
|
|
Progressive Motility
Time Frame: 16 weeks
|
This type of motility refers to sperm that swim progressively, mostly in a straight line or large circles.
|
16 weeks
|
|
DNA Fragmentation Index (DFI)
Time Frame: 16 weeks
|
Percentage of sperm with fragmented DNA
|
16 weeks
|
|
Testosterone
Time Frame: 16 weeks
|
Testosterone is the primary androgen in men and is synthesized in the testes.
It can be measured in the serum.
|
16 weeks
|
|
Sex Hormone-Binding Globulin (SHBG)
Time Frame: 16 weeks
|
SHBG is a protein that is produced by the liver and binds tightly to the hormones testosterone, dihydrotestosterone (DHT) and oestradiol, and transports them in the blood in an inactive form.
|
16 weeks
|
|
Reactive Oxygen Species (ROS)
Time Frame: 16 weeks
|
ROS is measured by oxidative colour change of luminol per second per million sperm.
|
16 weeks
|
|
Morphology
Time Frame: 16 weeks
|
the percentage of sperm that appear normal when semen is viewed under a microscope
|
16 weeks
|
|
Luteinizing Hormone (LH)
Time Frame: 16 weeks
|
LH produced in the pituitary gland, stimulates the leydig cells in the testes to produce testosterone.
|
16 weeks
|
|
Follicle Stimulating Hormone (FSH)
Time Frame: 16 weeks
|
FSH produced in the pituitary gland, stimulates the testes to produce mature sperm.
|
16 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Channa Jayasena, MD PhD, Imperial College London
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 18HH4412
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.